國立高雄大學圖資館 |

Language: English

Back

3D printing of pharmaceuticals

Basit, Abdul W.

3D printing of pharmaceuticals

Record Type:	Electronic resources : Monograph/item
Title/Author:	3D printing of pharmaceuticalsedited by Abdul W. Basit, Simon Gaisford.
other author:	Basit, Abdul W.
Published:	Cham :Springer International Publishing :2018.
Description:	xi, 240 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Pharmaceutical industryTechnological innovations.
Online resource:	http://dx.doi.org/10.1007/978-3-319-90755-0
ISBN:	9783319907550$q(electronic bk.)

3D printing of pharmaceuticals
3D printing of pharmaceuticals[electronic resource] /edited by Abdul W. Basit, Simon Gaisford. - Cham :Springer International Publishing :2018. - xi, 240 p. :ill., digital ;24 cm. - AAPS advances in the pharmaceutical sciences series,v.312210-7371 ;. - AAPS advances in the pharmaceutical sciences series ;3..

Paradigm of personalised medicines -- Pharmaceutical ink-jet printing -- Fused-deposition modelling (FDM) 3D printing -- Stereolithographic (SLA) 3D printing -- Selective laser sintering (SLS) 3D printing -- Flexographic 3D printing -- Semi-solid extrusion 3D printing -- Ink-jet printing for personalised dosing -- Printing crystal forms -- Printing of nanoparticle/polymer conjugates -- 3D Printing organ vasculature -- 3D printed ears -- Visualisation of 3D printed compartmental DDSs -- 3D printed medicines - A regulatory perspective -- Spritam - a case study -- 4D printing -- 3DP - costs and manufacturing issues -- Other non-pharmaceutical 3DP areas.

3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Professor Abdul Basit is a Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. His research has been translated into the design of new technologies and improved disease treatments, many of which have been commercialised. Abdul is also a serial entrepreneur and has filed multiple patents, is the recepient of several research awards and has founded 3 companies (Kuecept, Intract Pharma, FabRx) He further serves as a consultant to many pharmaceutical organisations and is on the advisory boards of scientific journals, healthcare and charitable bodies. Professor Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters, 4 authored books and is the recipient of multiple research awards. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, translating his expertise by co-founding FabRx. Simon is also an expert in the physicochemical characterisation of compounds and formulations with thermal methods and calorimetry.

ISBN: 9783319907550$q(electronic bk.)

Standard No.: 10.1007/978-3-319-90755-0doiSubjects--Topical Terms:

276225
Pharmaceutical industry
--Technological innovations.

LC Class. No.: HD9665.5

Dewey Class. No.: 338.476151

3D printing of pharmaceuticals
LDR:04283nmm a2200325 a 4500 001 543546
003 DE-He213
005 20190225102314.0
006 m d
007 cr nn 008maaau
008 190430s2018 gw s 0 eng d
020 $a 9783319907550$q(electronic bk.)
020 $a 9783319907543$q(paper)
024 7 $a 10.1007/978-3-319-90755-0 $2 doi
035 $a 978-3-319-90755-0
040 $a GP $c GP
041 0 $a eng
050 4 $a HD9665.5
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
082 0 4 $a 338.476151 $2 23
090 $a HD9665.5 $b .A111 2018
245 0 0 $a 3D printing of pharmaceuticals $h [electronic resource] / $c edited by Abdul W. Basit, Simon Gaisford.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xi, 240 p. : $b ill., digital ; $c 24 cm.
490 1 $a AAPS advances in the pharmaceutical sciences series, $x 2210-7371 ; $v v.31
505 0 $a Paradigm of personalised medicines -- Pharmaceutical ink-jet printing -- Fused-deposition modelling (FDM) 3D printing -- Stereolithographic (SLA) 3D printing -- Selective laser sintering (SLS) 3D printing -- Flexographic 3D printing -- Semi-solid extrusion 3D printing -- Ink-jet printing for personalised dosing -- Printing crystal forms -- Printing of nanoparticle/polymer conjugates -- 3D Printing organ vasculature -- 3D printed ears -- Visualisation of 3D printed compartmental DDSs -- 3D printed medicines - A regulatory perspective -- Spritam - a case study -- 4D printing -- 3DP - costs and manufacturing issues -- Other non-pharmaceutical 3DP areas.
520 $a 3D printing is forecast to revolutionise the pharmaceutical sector, changing the face of medicine development, manufacture and use. Potential applications range from pre-clinical drug development and dosage form design through to the fabrication of functionalised implants and regenerative medicine. Within clinical pharmacy practice, printing technologies may finally lead to the concept of personalised medicines becoming a reality. This volume aims to be the definitive resource for anyone thinking of developing or using 3D printing technologies in the pharmaceutical sector, with a strong focus on the translation of printing technologies to a clinical setting. This text brings together leading experts to provide extensive information on an array of 3D printing techniques, reviewing the current printing technologies in the pharmaceutical manufacturing supply chain, in particular, highlighting the state-of-the-art applications in medicine and discussing modern drug product manufacture from a regulatory perspective. This book is a highly valuable resource for a range of demographics, including academic researchers and the pharmaceutical industry, providing a comprehensive inventory detailing the current and future applications of 3D printing in pharmaceuticals. Professor Abdul Basit is a Professor of Pharmaceutics at the UCL School of Pharmacy, University College London. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. His research has been translated into the design of new technologies and improved disease treatments, many of which have been commercialised. Abdul is also a serial entrepreneur and has filed multiple patents, is the recepient of several research awards and has founded 3 companies (Kuecept, Intract Pharma, FabRx) He further serves as a consultant to many pharmaceutical organisations and is on the advisory boards of scientific journals, healthcare and charitable bodies. Professor Simon Gaisford holds a Chair in Pharmaceutics and is Head of the Department of Pharmaceutics at the UCL School of Pharmacy, University College London. He has published 110 papers, 8 book chapters, 4 authored books and is the recipient of multiple research awards. His research is focused on novel technologies for manufacturing medicines, particularly using ink-jet printing and 3D printing, translating his expertise by co-founding FabRx. Simon is also an expert in the physicochemical characterisation of compounds and formulations with thermal methods and calorimetry.
650 0 $a Pharmaceutical industry $x Technological innovations. $3 276225
650 0 $a Three-dimensional printing. $3 577142
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Pharmaceutical Sciences/Technology. $3 338426
650 2 4 $a Biomedical Engineering/Biotechnology. $3 730838
700 1 $a Basit, Abdul W. $3 821802
700 1 $a Gaisford, Simon. $3 302971
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a AAPS advances in the pharmaceutical sciences series ; $v 3. $3 559046
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-90755-0
950 $a Biomedical and Life Sciences (Springer-11642)